Yang Wang

Univ Of Massachusetts Med Sch Worcester

$570,083

Attributed

$1,819,706

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $694.3K · FY2015–22

$1M$750K$500K$250K$0

'15

'16

'17

'18

'19

'20

'21

'22

Funding mix

By agency

NIH$1,819,706 · 2

By mechanism

R01$1,359,081 · 1

R21$460,625 · 1

Top collaborators

Most similar at Univ Of Massachusetts Med Sch Worcester

Same institution · by research overlap

Zuoshang Xu$14,371,059
Celia A. Schiffer$33,871,325
Katherine A Fitzgerald$21,686,859
Daryl A Bosco$10,705,670
Jessica Lynn Cohen$158,538

Others in their field

Top investigators on “In Vivo”

David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
Dennis R. Burton · Scripps Research Institute$212,708,174
Mark S Klempner · Tufts Medical Center$128,021,180
Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200

Research focus

In VivoAnimal ModelProteinsAnimalsAntibody TherapyImmunotherapyIn VitroMutationVirusTherapeutic AntibodiesAntibody RepertoireBaseBetacoronavirusBindingAxonal TransportAntibodiesAmyotrophic Lateral SclerosisAstrocytesClinical TrialsCharacteristicsCombined Modality TherapyCommunicable DiseasesComplementAntiviral Agents

Grant awards (4)

Structure-guided and epitope-based design of potent and broadly neutralizing nanobodies for COVID-19 mucosal immunotherapy$694,299

R01 · FY2022 · AI · contact PI

Structure-guided and epitope-based design of potent and broadly neutralizing nanobodies for COVID-19 mucosal immunotherapy$664,782

R01 · FY2021 · AI · contact PI

A new antibody/RNAi combination therapy strategy for ALS$251,250

R21 · FY2016 · NS

A new antibody/RNAi combination therapy strategy for ALS$209,375

R21 · FY2015 · NS